News | December 10, 2025
Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
While Merck can appeal, Halozyme said it expects the order to hold
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
